1612763-44-6

Basic information

• Product Name: tert-butyl N-(furan-2-ylmethyl)-N-{4-[(3-oxo-2,3-dihydro-1,2-benzoxazol-2-yl)methyl]benzoyl}carbamate
• Synonyms: tert-butyl N-(furan-2-ylmethyl)-N-{4-[(3-oxo-2,3-dihydro-1,2-benzoxazol-2-yl)methyl]benzoyl}carbamate
• CAS NO: 1612763-44-6
• Molecular Weight: 448.475
• Mol File: 1612763-44-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: tert-butyl N-(furan-2-ylmethyl)-N-{4-[(3-oxo-2,3-dihydro-1,2-benzoxazol-2-yl)methyl]benzoyl}carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl N-(furan-2-ylmethyl)-N-{4-[(3-oxo-2,3-dihydro-1,2-benzoxazol-2-yl)methyl]benzoyl}carbamate(1612763-44-6)
• EPA Substance Registry System: tert-butyl N-(furan-2-ylmethyl)-N-{4-[(3-oxo-2,3-dihydro-1,2-benzoxazol-2-yl)methyl]benzoyl}carbamate(1612763-44-6)

Safety Data

• Hazardous Substances Data: 1612763-44-6(Hazardous Substances Data)

Upstream product

• 1094362-67-0 4-(chloromethyl)-N-(furan-2-ylmethyl)benzamide 
• 876-08-4 p-(chloromethyl)benzoyl chloride 
• 617-89-0 furan-2-ylmethanamine 
• 21725-69-9 1,2-benz-4-isooxazolin-3-one 
• 1612763-21-9 tert-butyl N-[4-(chloromethyl)benzoyl]-N-(furan-2-ylmethyl)carbamate 

Downstream Products

• 1612763-45-7 N-(furan-2-ylmethyl)-4-[(3-oxo-2,3-dihydro-1,2-benzoxazol-2-yl)methyl]benzamide 

Relevant articles and documents

Saccharin derivatives as inhibitors of interferon-mediated inflammation

A series of novel, saccharin-based antagonists have been identified for the interferon signaling pathway. Through in vitro high-throughput screening with the Colorado Center for Drug Discovery (C2D2) Pilot Library, we identified hit compound 1, which was the basis for extensive structure-activity relationship studies. Our efforts produced a lead anti-inflammatory compound, tert-butyl N-(furan-2-ylmethyl)-N-{4-[(1,1,3-trioxo-2,3-dihydro-1λ6,2- benzothiazol-2-yl)methyl]benzoyl}carbamate CU-CPD103 (103), as a potent inhibitor using an established nitric oxide (NO) signaling assay. With further studies of its inhibitory mechanisms, we demonstrated that 103 carries out this inhibition through the JAK/STAT1 pathway, providing a drug-like small molecule inflammation suppressant for possible therapeutic uses.